Systematic Review on the Cost Effectiveness of Prostate Cancer
Screening in Europe

J 2024

Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe

VYNCKIER, Pieter; Lieven ANNEMANS; Sarah RAES; Cheima AMROUCH; Peter LINDGREN et. al.

Basic information

Original name

Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe

Authors

VYNCKIER, Pieter; Lieven ANNEMANS; Sarah RAES; Cheima AMROUCH; Peter LINDGREN; Ondřej MÁJEK (203 Czech Republic, belonging to the institution); Katharina BEYER; Renee C A LEENEN; Lionne D F VENDERBOS; Frederique DENIJS; Meike J VAN HARTEN; Jozien HELLEMAN; Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution); Erik BRIERS; Vera VASILYEVA; Juan Gomez RIVAS; Partha BASU; Arunah CHANDRAN; Roderick C N VAN DEN BERGH; Sarah COLLEN; Hein VAN POPPEL and Monique J ROOBOL

Edition

European Urology, Amsterdam, Elsevier, 2024, 0302-2838

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30217 Urology and nephrology

Country of publisher

Netherlands

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 25.300 in 2023

RIV identification code

RIV/00216224:14110/24:00137808

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.eururo.2024.04.036

UT WoS

001356186700001

EID Scopus

2-s2.0-85194094867

Keywords in English

Prostate cancer; Screening; Cost effectiveness; PRostate cancer Awareness and Initiative for Screening in the European Union

Abstract

V originále

Background and objective: In Europe, prostate cancer (PCa) is the most common cancer in men. Screening may therefore be crucial to lower health care costs, morbidity, and mortality. This systematic review aimed to provide a contemporary overview of the costs and benefits of PCa screening programmes. Methods: A peer-reviewed literature search was conducted, using the PICO method. A detailed search strategy was developed in four databases based on the following key search terms: "PCa", "screening", and "cost effectiveness". Any type of economic evaluation was included. The search strategy was restricted to European countries, but no restrictions were set on the year of publication. Key findings and limitations: A total of 7484 studies were identified initially. Of these, 19 studies described the cost effectiveness of PCa screening in Europe. Among the studies using an initially healthy study population, most focussed on risk- and/or age- and/or magnetic resonance imaging (MRI)-based screening in addition to prostate-specific antigen (PSA) testing and compared this with no screening. Incremental cost ratios (ICERs) varied from 5872 per quality-adjusted life year (QALY) to 372 948/QALY, with a median of 56 487/QALY. Risk-based screening followed by MRI testing seemed to be a more cost-effective strategy than no screening. Conclusions and clinical implications: This systematic review indicates that screening programmes incorporating a risk-based approach and MRI have the potential to be cost effective. Patient summary: In this review, we looked at the cost effectiveness of prostate cancer screening in Europe. We found that a risk-based approach and incorporation of magnetic resonance imaging has the potential to be cost effective. However, there remains a knowledge gap regarding cost effectiveness of prostate cancer screening. Therefore, determinants of cost effectiveness require further investigation. (c) 2024 Published by Elsevier B.V. on behalf of European Association of Urology.

Cite

VYNCKIER, Pieter; Lieven ANNEMANS; Sarah RAES; Cheima AMROUCH; Peter LINDGREN; Ondřej MÁJEK; Katharina BEYER; Renee C A LEENEN; Lionne D F VENDERBOS; Frederique DENIJS; Meike J VAN HARTEN; Jozien HELLEMAN; Renata CHLOUPKOVÁ; Erik BRIERS; Vera VASILYEVA; Juan Gomez RIVAS; Partha BASU; Arunah CHANDRAN; Roderick C N VAN DEN BERGH; Sarah COLLEN; Hein VAN POPPEL and Monique J ROOBOL. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. European Urology. Amsterdam: Elsevier, 2024, vol. 86, No 5, p. 400-408. ISSN 0302-2838. Available from: https://dx.doi.org/10.1016/j.eururo.2024.04.036.

@article{2455471,
   author = {Vynckier, Pieter and Annemans, Lieven and Raes, Sarah and Amrouch, Cheima and Lindgren, Peter and Májek, Ondřej and Beyer, Katharina and Leenen, Renee C A and Venderbos, Lionne D F and Denijs, Frederique and van Harten, Meike J and Helleman, Jozien and Chloupková, Renata and Briers, Erik and Vasilyeva, Vera and Rivas, Juan Gomez and Basu, Partha and Chandran, Arunah and van den Bergh, Roderick C N and Collen, Sarah and Van Poppel, Hein and Roobol, Monique J},
   article_location = {Amsterdam},
   article_number = {5},
   doi = {http://dx.doi.org/10.1016/j.eururo.2024.04.036},
   keywords = {Prostate cancer; Screening; Cost effectiveness; PRostate cancer Awareness and Initiative for Screening in the European Union},
   language = {eng},
   issn = {0302-2838},
   journal = {European Urology},
   title = {Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe},
   url = {https://www.sciencedirect.com/science/article/pii/S0302283824023789?via%3Dihub},
   volume = {86},
   year = {2024}
}

TY  - JOUR
ID  - 2455471
AU  - Vynckier, Pieter - Annemans, Lieven - Raes, Sarah - Amrouch, Cheima - Lindgren, Peter - Májek, Ondřej - Beyer, Katharina - Leenen, Renee C A - Venderbos, Lionne D F - Denijs, Frederique - van Harten, Meike J - Helleman, Jozien - Chloupková, Renata - Briers, Erik - Vasilyeva, Vera - Rivas, Juan Gomez - Basu, Partha - Chandran, Arunah - van den Bergh, Roderick C N - Collen, Sarah - Van Poppel, Hein - Roobol, Monique J
PY  - 2024
TI  - Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe
JF  - European Urology
VL  - 86
IS  - 5
SP  - 400-408
EP  - 400-408
PB  - Elsevier
SN  - 03022838
KW  - Prostate cancer
KW  - Screening
KW  - Cost effectiveness
KW  - PRostate cancer Awareness and Initiative for Screening in the European Union
UR  - https://www.sciencedirect.com/science/article/pii/S0302283824023789?via%3Dihub
N2  - Background and objective: In Europe, prostate cancer (PCa) is the most common cancer in men. Screening may therefore be crucial to lower health care costs, morbidity, and mortality. This systematic review aimed to provide a contemporary overview of the costs and benefits of PCa screening programmes. Methods: A peer-reviewed literature search was conducted, using the PICO method. A detailed search strategy was developed in four databases based on the following key search terms: "PCa", "screening", and "cost effectiveness". Any type of economic evaluation was included. The search strategy was restricted to European countries, but no restrictions were set on the year of publication. Key findings and limitations: A total of 7484 studies were identified initially. Of these, 19 studies described the cost effectiveness of PCa screening in Europe. Among the studies using an initially healthy study population, most focussed on risk- and/or age- and/or magnetic resonance imaging (MRI)-based screening in addition to prostate-specific antigen (PSA) testing and compared this with no screening. Incremental cost ratios (ICERs) varied from 5872 per quality-adjusted life year (QALY) to 372 948/QALY, with a median of 56 487/QALY. Risk-based screening followed by MRI testing seemed to be a more cost-effective strategy than no screening. Conclusions and clinical implications: This systematic review indicates that screening programmes incorporating a risk-based approach and MRI have the potential to be cost effective. Patient summary: In this review, we looked at the cost effectiveness of prostate cancer screening in Europe. We found that a risk-based approach and incorporation of magnetic resonance imaging has the potential to be cost effective. However, there remains a knowledge gap regarding cost effectiveness of prostate cancer screening. Therefore, determinants of cost effectiveness require further investigation. (c) 2024 Published by Elsevier B.V. on behalf of European Association of Urology.
ER  -

VYNCKIER, Pieter; Lieven ANNEMANS; Sarah RAES; Cheima AMROUCH; Peter LINDGREN; Ondřej MÁJEK; Katharina BEYER; Renee C A LEENEN; Lionne D F VENDERBOS; Frederique DENIJS; Meike J VAN HARTEN; Jozien HELLEMAN; Renata CHLOUPKOVÁ; Erik BRIERS; Vera VASILYEVA; Juan Gomez RIVAS; Partha BASU; Arunah CHANDRAN; Roderick C N VAN DEN BERGH; Sarah COLLEN; Hein VAN POPPEL and Monique J ROOBOL. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. \textit{European Urology}. Amsterdam: Elsevier, 2024, vol.~86, No~5, p.~400-408. ISSN~0302-2838. Available from: https://dx.doi.org/10.1016/j.eururo.2024.04.036.

Přehled o publikaci